Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece

**Background:** Non-small cell lung cancer (NSCLC), which accounts for about 80%-85% of lungcancer cases, is a leading cause of cancer-related death worldwide. Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of patients with advanced, ALK...

Full description

Bibliographic Details
Main Authors: George Gourzoulidis, Oresteia Zisimopoulou, Nadia Boubouchairopoulou, Christina Michailidi, Chrissy Lowry, Charalampos Tzanetakos, Georgia Kourlaba
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2022-02-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://jheor.scholasticahq.com/article/31983-cost-effectiveness-analysis-of-lorlatinib-in-patients-previously-treated-with-anaplastic-lymphoma-kinase-inhibitors-for-non-small-cell-lung-cancer-in.pdf

Internet

https://jheor.scholasticahq.com/article/31983-cost-effectiveness-analysis-of-lorlatinib-in-patients-previously-treated-with-anaplastic-lymphoma-kinase-inhibitors-for-non-small-cell-lung-cancer-in.pdf

Similar Items